Amid $1B downsizing, Biogen lists Boston-area office space for sublease Johnson & Johnson's head of R&D Mathai Mammen heads for the exit in surprise move Rockley Photonics books commercial rollout of biosensing wristband with mystery customer Health bill brings new liabilities to Part D plans but possible boon on drug costs, experts say In warranty program, Pfizer will refund up to $50K for patients who discontinue use of rare disease drug AstraZeneca-Daiichi Sankyo's ADC barrels forward as Keytruda combo data make case for lung cancer use Boston Scientific investigating whistleblower claims of anti-bribery law violations Kaiser Permanente scrapes out 0.4% operating margin but loses big on investments in Q2 Struggling Novavax halves its sales forecast as COVID shot launch sputters Merck is back in Alzheimer's saddle with $1B+ Cerevance pact, years after dropping the BACE The rise of SkyWalker: FDA clears surgical robot for orthopedic procedures Excluding race and ethnicity data makes algorithm bias worse, Health Affairs study warns. Instead, here's what to do Acadia culls painkiller rival to Vertex and cancer candidate over poor data Featured Story | By Zoey Becker As Biogen's sales tumble in the wake of its troubled Aduhelm launch, the company is looking to exit some office space in the Boston area. Biogen has listed more than 183,500 square feet of office space for sublease at one of its five buildings in Cambridge, Massachusetts. read more |
| |
|---|
|
Top Stories By James Waldron Johnson & Johnson’s head of R&D is off. In a surprise post-market announcement yesterday, the company revealed that its executive vice president of pharma R&D Mathai Mammen, M.D., Ph.D, is leaving to “pursue other opportunities.” read more By Andrea Park The “Baseline” version of Rockley Photonics’ Bioptx wristband could be on consumers’ arms as soon as the end of this year, the company said Tuesday, now that it has received the first commercial purchase order for the devices. read more By Robert King The Inflation Reduction Act that passed the Senate Sunday after a marathon session could substantially shift liability for catastrophic Part D costs from Medicare onto the plan, experts said. read more By Kevin Dunleavy Last year Pfizer introduced its first warranty program, using it to promote lung cancer drug Xalkori. Now the company has opened a similar program for newly approved Panzyga, which treats the rare disorder chronic inflammatory demyelinating polyneuropathy (CIPD). read more By Nick Paul Taylor AstraZeneca and Daiichi Sankyo have delivered more evidence that their TROP2-directed antibody-drug conjugate (ADC) may have a future in non-small cell lung cancer, linking the candidate to a roughly 40% overall response rate when used as part of doublet and triplet combination therapies. read more By Andrea Park A whistleblower letter from March claims Boston Scientific has violated the Foreign Corrupt Practices Act in Vietnam; the company said it “is cooperating with government agencies while investigating these allegations.” read more By Dave Muoio Whereas Kaiser Permanente reported a $2.62 billion gain from investments and other income a year ago, the nonprofit juggernaut weathered a $1.39 billion loss in the category due to the most recent quarter's struggling investment markets, according to new financial filings. read more By Fraiser Kansteiner Novavax pulled down just $186 million in second quarter revenues, charting $78 million in sales of its protein-based COVID shot. That's a far cry from the $605 million in vaccine revenue Novavax generated over the first three months of the year. read more By Annalee Armstrong Another Big Pharma is entering—or rather re-entering—the Alzheimer’s ring. Merck & Co. has signed a billion-dollar biobucks deal with Cerevance to identify new therapies for the devastating neurodegenerative disease. read more By Andrea Park Not so long ago in our very own galaxy, the FDA saw fit to expand its list of authorized robotic surgery systems—no epic interplanetary battles needed. read more By Anastassia Gliadkovskaya While a common precaution might be removing race and ethnicity data altogether, “this approach is misguided.” Instead, this data can be estimated using existing validated methods. read more By James Waldron Acadia ditched two candidates from its pipeline, including a one-time competitor to Vertex’s non-opioid painkiller. The biotech revealed it scrapped ACP-044 following an evaluation of the final phase 2 data on patients undergoing bunion removal, while a phase 1 cancer prospect will not move forward. read more Resources Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. | 